Illumina (NASDAQ: ILMN) reported Q1 EPS of $1.60, $0.24 better than the analyst estimate of $1.36. Revenue for the quarter came in at $846 million versus the consensus estimate of $835.53 million.

“This was a strong start to the year, with $846 million in revenue and more than $1 billion in orders for the first time in Illumina’s history,” said Francis deSouza, President and CEO. “Our growth is driven by a broad range of sequencing applications, with 14% sequencing consumable growth in the first quarter, including more than 20% growth in clinical sequencing consumables.”

For earnings history and earnings-related data on Illumina (ILMN) click here.